{
  "id": 121485,
  "title": "LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care",
  "url": "https://urgent.news/2026/08/04/labpmm-launches-global-kmt2a-mrd-testing-service-to-support-menin",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-04T07:11:58.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/labpmm-launches-global-kmt2a-mrd-testing-service-to-support-menin-inhibitor-development-and-acute-leukemia-care"
  },
  "original_language": "en",
  "account": null,
  "summary": "SAN DIEGO — LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}